MedTrace Logo

Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain

NCT00799656 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2011-04-01

No results posted yet for this study

Summary

The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain.

The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.

Conditions

Interventions

DRUG

ataciguat (HMR1766)

oral administration 200mg once daily for 28 days

DRUG

placebo

oral administration once daily for 28 days

Sponsors & Collaborators

Principal Investigators

  • Hans-Goerg Kress, Professor · Medizinische Universität / AKH Wien - Währinger Gürtel 18-20 - A-1090 Wien

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-06-30
Completion
2009-09-30

Countries

  • Austria
  • Czechia
  • Romania

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00799656 on ClinicalTrials.gov